ubspecialist Tips for the Multispecialist is designed to provide a clinically-focused update on the most current imaging guidelines, terminology, and disease classifications. Incorporating consistent terminology and up-to-date national and international recommendations into imaging reports can boost communication between radiologists and clinicians, resulting in better patient care. Imaging reports that are consistent, focused, and based upon evidence-based medicine are expected in the current environment of value-based reimbursement and healthcare payment reforms.
This book offers 30 AMA Category 1 Credits™ and 30 American Board of Radiology^©, MOC Part II, Self-Assessment CME (SA-CME) following completion of an online test. Soft bound book; 305 pages; 40 chapters.

The target audience for this activity is radiologists who read and interpret imaging in multiple subspecialties.

After completing the material in this article, the learner should be able to:

1. Identify current white papers, ACR Appropriateness Criteria™, and other national and international guidelines that encourage best practices across multiple subspecialties.
2. Describe critical imaging findings in adult and pediatric patients with diseases of the gastrointestinal tract, genitourinary, and musculoskeletal system.
3. Describe and implement LI-RADS™ for reporting of liver lesions in patients with cirrhosis.
4. List updated concepts in prostate MRI, including PI-RADS™ and MRI-targeted biopsy.

ARRS staff involved with this activity have nothing to disclose. Below is a listing of activity’s contributors and planners disclosures:

Planners

• A. Paladin has nothing to disclose.
• L. Bancroft receives royalties from Lippincott and a speaking honorarium from World Class CME.
• R. Iyer has nothing to disclose.
• T. Tailor has nothing to disclose.
• A. Paladin has nothing to disclose.

Module 1 – Chest Imaging

• D. Naeger has nothing to disclose.
• J. Chung receives royalties from Elsevier/Amirsys. Dr. Chung receives consultant fees from Boehringer Ingelheim, Genentech, and Veracte and speaker fees from Boehringer Ingelheim and Genentech.
• J. Bueno has nothing to disclose.
• B. Carter receives royalties from Elsevier.

Module 2 – Cardiovascular Imaging

• T. Tailor has nothing to disclose.
• C. Raptis has nothing to disclose.
• S. Azizaddini has nothing to disclose.
• S. Bhalla has nothing to disclose.
• S. Abbara receives royalties from Elsevier Amirsys.
• P. Ranganath has nothing to disclose.
• H. Goerne has nothing to disclose.
• K. Ordovas is a member of the research support/advisory board for GE Healthcare Arterys.
• J. Rodriguez-Ortiz has nothing to disclose.

Module 3 – Hepatobiliary Imaging

• W. Masch receives travel expenses and a stipend as a consultant for Bayer AG.
• A. Costa has nothing to disclose.
• J. Kang has nothing to disclose.
• E. Stueck has nothing to disclose.
• S. Thipphavong has nothing to disclose.
• A. Costa has nothing to disclose.
• L. Alexander’s spouse owns stock in GE, Abbott Laboratories, and AbbVie, Inc.
• A. Metcalfe has nothing to disclose.
• J. LeGout has nothing to disclose.
• C. Bolan has nothing to disclose.
• K. Cox has nothing to disclose.
• C. van der Pol has nothing to disclose.
• D. Kurowecki has nothing to disclose.
• A. Kulkarni has nothing to disclose.
• J. Satkunasingham has nothing to disclose.

Module 4 – Pancreas Imaging

• J. Z. Wang has nothing to disclose.
• R. Kelley has nothing to disclose.
• K. Sandrasegaran has nothing to disclose.
• E. Tamm has nothing to disclose.
• O. Le has nothing to disclose.
• S. Javadi has nothing to disclose.
• P. Bhosale has nothing to disclose.
• A. Kambadakone has nothing to disclose.
• A. Pourvani has nothing to disclose.
• A. Negreros-Osuna has nothing to disclose.
• D. Knipp has nothing to disclose.

Module 5 – Genitourinary Imaging

• M. Davenport is a consultant for NCI and the FDA. Dr. Davenport receives book royalties from Wolters Kluwer.
• A. Bowman has nothing to disclose.
• J. LeGout has nothing to disclose.
• A. Alagely has nothing to disclose.
• A. Kielar receives research funding from GE.
• S. Jerayaj has nothing to disclose.
• N. Schieda has nothing to disclose.
• A. Venkatesan receives grant support from the RSNA and Toshiba American Medical Systems.

Module 6 – Gastrointestinal Imaging

• E. Paulson has nothing to disclose.
• K. Kalisz has nothing to disclose.
• B. Wildman-Tobriner has nothing to disclose.
• B. Allen has nothing to disclose.
• T. Jaffe has nothing to disclose.
• J. Yee has research grants from Echopixel and Philips.
• S. Thipphavong has nothing to disclose.
• A. Costa has nothing to disclose.
• K. Jharveri has nothing to disclose.
• J. Sammon has nothing to disclose.

Module 7 – Women’s Imaging

• K. Johnson has nothing to disclose.
• S. Chou has nothing to disclose.
• R. Miles has nothing to disclose.
• S. Call has nothing to disclose.
• J. Revels has nothing to disclose.
• M. Moshiri receives consultant fees from Amirsys.
• E. Soloff has nothing to disclose.
• S. Chou has nothing to disclose.
• D. Baumgarten has nothing to disclose.

Module 8 – Musculoskeletal Imaging

• M. Pathria has nothing to disclose.
• C. Chung has nothing to disclose.
• L. Bancroft receives royalties from Lippincott and a speaking honorarium from World Class CME.
• J. Dennison has nothing to disclose.
• A. Leyva has nothing to disclose.
• B. Manchec has nothing to disclose.
• A. Cibulas has nothing to disclose.
• K. Scherer has nothing to disclose.
• C. Wasyliw has nothing to disclose.
• J. Porrino has nothing to disclose.
• J. Jacobson has nothing to disclose.

Module 9 – Pediatric Imaging

• S. Milla has nothing to disclose.
• C. Watterson has nothing to disclose.
• B. Brown has nothing to disclose.
• L. Delaney has nothing to disclose.
• A. Stanescu has nothing to disclose.
• R. Iyer has nothing to disclose.

Module 10 – Neuroradiology

• A. Kuner has nothing to disclose.
• A. Greyev has nothing to disclose.
• K. Hawk has nothing to disclose.
• R. Bray has nothing to disclose.
• A. Khalil has nothing to disclose.
• V. Shah has nothing to disclose.
• J. Fink receives salary support as a site co-investigator for Guerbet, LLC and AbbVie.